RMTG (Regenerative Medical Technology Group) Total Debt per Share: $1.58 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerative Medical Technology Group Total Debt per Share?

Regenerative Medical Technology Group RMTG -4.47% Total Debt per Share is $1.58 as of Jun. 2026. The stock has 3 warning signs investors should review.

$1.58 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Regenerative Medical Technology Group's Total Debt Per Share for the quarter that ended in Jun. 2026 was $1.58.


Regenerative Medical Technology Group Total Debt per Share Related Terms


Regenerative Medical Technology Group Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Regenerative Medical Technology Group's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerative Medical Technology Group Total Debt per Share Chart

Regenerative Medical Technology Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only 1.13 1.22 1.41 1.60 1.49

Regenerative Medical Technology Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.66 1.49 1.49 1.57 1.58

Regenerative Medical Technology Group Total Debt per Share Calculation

Regenerative Medical Technology Group's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Regenerative Medical Technology Group's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $1.58 mean?
Regenerative Medical Technology Group (RMTG) has a Total Debt per Share of $1.58 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Regenerative Medical Technology Group and its competitors.
Is Regenerative Medical Technology Group's Total Debt per Share too high?
Regenerative Medical Technology Group's current Total Debt per Share is $1.58.
How does Regenerative Medical Technology Group's Total Debt per Share compare to ABPO and CLSDQ?
Regenerative Medical Technology Group's Total Debt per Share of $1.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Regenerative Medical Technology Group and its competitors. Regenerative Medical Technology Group's current Total Debt per Share is $1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Fairly Valued. The stock's GF Value™ is $0.08, compared to a current price of $0.09 — trading 7.5% above its estimated fair value. The current Total Debt per Share is $1.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Total Debt per Share is $1.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerative Medical Technology Group Business Description

Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.